In a post hoc analysis of phase 3 SELECT-COMPARE and SELECT-PsA 1 trials, upadacitinib and adalimumab both reduced patient-reported pain vs placebo in rheumatoid arthritis and psoriatic arthritis, including among patients with attenuation of objective inflammation, with greater magnitude of pain reduction observed with upadacitinib vs adalimumab in rheumatoid arthritis. Mediation analyses suggested that pain improvement was driven by both indirect anti-inflammatory effects and direct effects independent of measured inflammatory markers, supporting a potential role for Janus kinase inhibition in modulating inflammatory and non-inflammatory pain pathways.

Source: RMD Open